Fortunately, immunotherapy based on immune checkpoint blockade (ICB) to interfere with programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) has attracted tremendous interests in the field of cancer treatment and has shown great therapeutic effects in recent years. The gene discussed is PDCD1; the disease is cancer.